AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia

BioEssays

Volumn 22, Issue 3, 2000, Pages 214-218

  Barton, Kevin ^a   Nucifora, Giuseppina ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; ONCOPROTEIN; RUNX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; TUMOR PROTEIN;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; GENE DOSAGE; GENETIC PREDISPOSITION; GENETICS; HUMAN; LEUKEMIA;

ACUTE DISEASE; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA; LEUKEMIA, MYELOCYTIC, ACUTE; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

EID: 0034012933     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-1878(200003)22:3<214::AID-BIES2>3.0.CO;2-I     Document Type: Article

References (42)

1. Song W-J, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy D-C, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia. Nat Gen 1999;23:166-175.
2. Kagoshima H, Shigesada K, Satake M, Ito Y. The Runt domain identifies a new family of heterodimeric transcription factors. Trends Genet 1993;9-338-341.
3. Ogawa E, Maruyama M, Kagoshima H, Inuzaka M, Lu J, Satake M, Shigesada K, Ito Y. PEBP2/PEA2 represents a family of transcription factor homologous to the products of the Drosophila Runt gene and the human AML1. Proc Natl Acad Sci USA 1993;90:6859-6863.
4. Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Ohki M. The t(8:21) breakpoints on chromosome 21 in acute myeloid leukemia clustered within a limited region of a novel gene, AML1. Proc Natl Acad Sci USA 1991;88:10431-10435.
5. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y, AML1, AML2, and AML3 the human members of the runt-domain gene-family: cDNA structure, expression, and chromosomal location. Genomics 1994;23:425-432.
6. Uchida H, Zhang J, Nimer D. AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol 1997;158:2251-2258.
7. Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert SW, Friedman AD. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP@b/CBFb proto-oncoproteins, regulates the murine MPO and NE genes in immature myeloid cells. Mol Cell Biol 1994;14:5558-5568.
8. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer D. The AML1/ ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 1995;11:2667-2674.
9. Rhoades KL, Hetherington CJ, Rowley JD. Hiebert SW, Nucifora G, Tenen DG, Zhang D-E. Synergistic up-regulation of the myeloid specific M-CSF receptor promoter by AML1 and the t(8:21) fusion protein may contribute to leukemogenesis Proc Natl Acad Sci USA 1996;93:11895-11900.
10. Dowton SB, Beardsley D, Jamison D, Blattner S, Li FP. Studies of a familial platelet disorder. Blood 1995;65:557-563.
11. Ho CY, Otterud B, Legare RD, Varvil T, Saxena R, DeHart DB, Kohler SE, Aster JC, Dowton SB, Li FP, Leppert M, Gilliland DG. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood 1996;87:5218-5224.
12. Arepally G, Rebbeck TR, Song W, Gilliland G, Maris JM, Ponce M. Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML). Blood 1998;92:2600-2602.
13. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki, H, Okubo, T, Suzushima H, Takatsuki K, Kanno T, Shigesada K, Ito Y. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEP2aB gene associated with myeloblastic leukemias. Blood 1999;93: 1817-1824.
14. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GWH, Beddington RSP, Mundlos S, Olsen BR, Selby PB, Owen MJ. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997;89:765-771.
15. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Kroll JHM, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997;89:773-779.
16. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentation. Cell 1997;89: 747-754.
17. Komori T, Yagi H, Nomura S, Yamaguchi A. Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao Y-H, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755-764.
18. Zhou G, Chen Y, Zhou L, Thirunavukkarasu K, Hecht J, Chitayat D. Gelb BD, Pirinen S, Berry SA, Greenberg CR, Karsenty G, Lee B. CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. Hum Mol Genet 1999;8:2311-2316.
19. Svarch E, Menendez A, Morales M, Gonzalez A. Juvenile chronic myelogenous leukaemia and cleidocranial dysostosis. Haematologia 1988;21:121-122.
20. Le XF, Groner Y, Kornblau SM, Gu Y, Hittelman WN, Levanon D, Mehta K, Arlinghaus RB, Chang KS. Regulation of AML2/CBFA3 in hematopoietic cells through the retinoic acid receptor alpha-dependent signaling pathway. J Biol Chem 1999;274:21651-21658.
21. Horwitz M, Sabath DE, Smithson WA, Radich J. A family inheriting different subtypes of acute myelogenous leukemia. Am J Hematol 1996;52:295-304.
22. Olopade OI, Roulston D, Baker T, Narvid S, Le Beau MM, Freireich EJ, Larson RA, Golomb HM. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia 1996;10:669-674.
23. Nucifora G, Rowley JD. AML1 in the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995;86:1-14.
24. Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N, Ohki M. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993;12: 2715-2721.
25. Nucifora G, Dickstein JI, Torbenson V, Rowley JD, Vardiman JW. Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21), Leukemia 1994;8:1533-1539.
26. Nucifora G, Birn D, Erickson P, Gao J, Le Beau M, Drabkin H, Rowley JD. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) AML. Blood 1993;81: 888-894.
27. Nucifora G, Larson RA, Rowley JD. Persistence of the t(8;21) in AML-M2 long-term remission patients. Blood 1993;82:712-715.
28. Fears S, Vignon C, Bohlander SK, Smith S, Rowley JD, Nucifora G. Correlation between the TEL/AML1 fusion gene and karyotypic abnormalities in children with B-cell ALL. Genes Chrom Cancer 1996;17: 127-135.
29. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor b to a novel Ets-like gene, Tel, in chronic myelomonocytic leukemia with t(5;21) chromosomal translocation. Cell 1994;77:307-315.
30. Liu P, Tarle SA, Hajra A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS. Fusion between transcription factor CBFb/PEBP2b and a myosin heavy chain in acute myeloid leukemia. Science 1993;261: 1041-1044.
31. Nucifora G, Birn D, Espinosa R, LeBeau M, Erickson P, Roulston D, McKeitnan TW, Drabkin H, Rowley JD. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 1993;81:2728-2733.
32. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in Human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996;84: 321-330.
33. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes neucrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 1996;93:3444-3449.
34. Wang Q, Stacy T, Miller JD, Lewis AF, Gu T-L, Huang X, Bushweller JH, Bories J-C. Alt FW, Ryan G, Liu PP, Wynshaw-Boris A, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. The CBFb subunit is essential for CBFa2 (AML1) function in vivo. Cell 1996;87:697-708.
35. Sasaki K, Yagi H, Bronson RT, Tominaga K, Matsunashi T, Deguchi K, Tani Y, Kishmoto T, Komori T. Absence cf fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor b. Proc Natl Acad Sci 1996;93:12359-12363.
36. Castilla LH, Wijmenga C, Wang Q, Stacy T, Speck NA, Eckhaus M, Marin-Padilla M, Collins FS, Wynshaw-Boris A, Liu PP. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 1996; 87:687-696.
37. Yergeau DA. Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, Marin-Padilla M, Tenen DG, Speck NA, Zhang D-E. Embryonic lethality and impairment of naematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Gen 1997;15:303-306.
38. Okuda T, Cai Z, Yang S, Lenny N, Lyu C-j, van Deursen JMA, Harada H, Downing JR. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic nematopoietic progenitors. Blood 1998;91: 3134-3143.
39. Kivivuori S, Rajantie J, Simes M. Peripheral blood cell counts in infants with Down's syndrome. Clinical Genetics 1996;49:15-19.
40. Huret J, Leonard C. Chromosome 21 and platelets: a gene dosage effect? Clinical Genetics 1997;31:140-141.
41. Loncarevic I, Roitzheim B, Ritterbach J, Viehmann S, Borkhardt A, Lampert F, Harbott J. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion. Genes Chrom Cancer 1999;24:272-277.
42. Berger R, Acute lymphoblastic leukemia and chromosome 21. Cancer Genet Cytogenet 1997;94:8-12.